IL238605A - Converted pyrimidine compounds with alkylamide for use in modulation il-23, il-12, and / or ifnα - Google Patents

Converted pyrimidine compounds with alkylamide for use in modulation il-23, il-12, and / or ifnα

Info

Publication number
IL238605A
IL238605A IL238605A IL23860515A IL238605A IL 238605 A IL238605 A IL 238605A IL 238605 A IL238605 A IL 238605A IL 23860515 A IL23860515 A IL 23860515A IL 238605 A IL238605 A IL 238605A
Authority
IL
Israel
Prior art keywords
ifnα
alkylamide
modulation
compounds useful
pyrimidine compounds
Prior art date
Application number
IL238605A
Other languages
English (en)
Hebrew (he)
Other versions
IL238605A0 (en
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL238605A0 publication Critical patent/IL238605A0/en
Publication of IL238605A publication Critical patent/IL238605A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
IL238605A 2012-11-08 2015-05-04 Converted pyrimidine compounds with alkylamide for use in modulation il-23, il-12, and / or ifnα IL238605A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723827P 2012-11-08 2012-11-08
PCT/US2013/068866 WO2014074670A1 (en) 2012-11-08 2013-11-07 ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα

Publications (2)

Publication Number Publication Date
IL238605A0 IL238605A0 (en) 2015-06-30
IL238605A true IL238605A (en) 2017-05-29

Family

ID=49667570

Family Applications (1)

Application Number Title Priority Date Filing Date
IL238605A IL238605A (en) 2012-11-08 2015-05-04 Converted pyrimidine compounds with alkylamide for use in modulation il-23, il-12, and / or ifnα

Country Status (14)

Country Link
US (1) US9540333B2 (enExample)
EP (1) EP2917186B1 (enExample)
JP (1) JP6266639B2 (enExample)
KR (1) KR102205914B1 (enExample)
CN (1) CN104903301B (enExample)
AU (1) AU2013341195B2 (enExample)
BR (1) BR112015009798A2 (enExample)
CA (1) CA2890935A1 (enExample)
EA (1) EA028052B1 (enExample)
ES (1) ES2648226T3 (enExample)
IL (1) IL238605A (enExample)
MX (1) MX2015005561A (enExample)
SG (1) SG11201503395TA (enExample)
WO (1) WO2014074670A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35126A (es) 2012-11-08 2014-05-30 Bristol Myers Squibb Co Ojo es alfa
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
EP3080131B1 (en) 2013-12-10 2018-10-10 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
MA46620A (fr) * 2016-10-28 2021-05-26 Bristol Myers Squibb Co Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
CN107857754B (zh) * 2018-01-15 2018-11-09 泰山医学院 一种化合物及其在制备预防/治疗类风湿性关节炎药物中的应用
TW201940483A (zh) 2018-03-12 2019-10-16 美商艾伯維有限公司 酪胺酸激酶2介導的傳訊之抑制劑
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CA3138473A1 (en) * 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
KR20230159419A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
MX2023009685A (es) 2021-02-19 2023-10-30 Sudo Biosciences Ltd Inhibidores de tyk2 y sus usos.
MX2024004993A (es) 2021-10-25 2024-05-07 Kymera Therapeutics Inc Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos.
WO2024257023A1 (en) 2023-06-14 2024-12-19 Alembic Pharmaceuticals Limited Tyk2 pseudokinase ligands and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
JP4529685B2 (ja) 2002-06-28 2010-08-25 アステラス製薬株式会社 ジアミノピリミジンカルボキサミド誘導体
KR20050019797A (ko) * 2002-06-28 2005-03-03 야마노우치세이야쿠 가부시키가이샤 디아미노피리미딘카르복사미드 유도체
CN101027288B (zh) * 2004-09-30 2013-04-17 泰博特克药品有限公司 抑制hiv的5-取代嘧啶
WO2006068770A1 (en) * 2004-11-24 2006-06-29 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
CN101405283B (zh) * 2006-03-30 2014-06-18 泰博特克药品有限公司 Hiv抑制性5-酰氨基取代的嘧啶类化合物
CN101506177A (zh) * 2006-07-21 2009-08-12 诺瓦提斯公司 作为jak激酶抑制剂的2,4-二(芳基氨基)-嘧啶-5-酰胺化合物
WO2009145856A1 (en) * 2008-04-16 2009-12-03 Portola Pharmaceuticals, Inc. 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors
KR101773313B1 (ko) * 2008-04-16 2017-08-31 포톨라 파마슈티컬스, 인코포레이티드 syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
AR076550A1 (es) * 2009-05-06 2011-06-22 Portola Pharm Inc Inhibidores de la janus tirosina kinasa (jak)
ES2444777T3 (es) * 2009-06-12 2014-02-26 Bristol-Myers Squibb Company Compuestos de nicotinamida útiles como moduladores de quinasas
WO2011065800A2 (ko) * 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
UA120740C2 (uk) * 2011-04-22 2020-02-10 Сігнал Фармасьютікалз, Елелсі Заміщені діамінокарбоксамідні і діамінокарбонітрильні похідні піримідинів, їх композиції і способи лікування з їх допомогою
UY35126A (es) 2012-11-08 2014-05-30 Bristol Myers Squibb Co Ojo es alfa
EA028526B1 (ru) 2012-11-08 2017-11-30 Бристол-Майерс Сквибб Компани АЛКИЛАМИДЗАМЕЩЕННЫЕ ПИРИДИЛЬНЫЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОТВЕТОВ, ОПОСРЕДУЕМЫХ IL-12, IL-23 И/ИЛИ IFNα
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa

Also Published As

Publication number Publication date
CN104903301A (zh) 2015-09-09
AU2013341195B2 (en) 2017-09-21
AU2013341195A1 (en) 2015-07-02
JP2016501185A (ja) 2016-01-18
EP2917186B1 (en) 2017-10-18
CN104903301B (zh) 2017-08-29
WO2014074670A1 (en) 2014-05-15
US20150299139A1 (en) 2015-10-22
JP6266639B2 (ja) 2018-01-24
EA201590911A1 (ru) 2015-10-30
IL238605A0 (en) 2015-06-30
EA028052B1 (ru) 2017-10-31
US9540333B2 (en) 2017-01-10
BR112015009798A2 (pt) 2017-07-11
MX2015005561A (es) 2015-07-23
ES2648226T3 (es) 2017-12-29
KR102205914B1 (ko) 2021-01-20
EP2917186A1 (en) 2015-09-16
SG11201503395TA (en) 2015-05-28
KR20150079678A (ko) 2015-07-08
CA2890935A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
IL238605A (en) Converted pyrimidine compounds with alkylamide for use in modulation il-23, il-12, and / or ifnα
HUS2300025I1 (hu) Amidszubsztituált heterociklikus vegyületek mint IL-12, IL-23 és/vagy IFN-ALFA modulátorai
IL238554A0 (en) Alkyl-amide substituted pyridyl compounds are useful as modulators of il12, il23, and/or ifnα responses
IL253950B (en) Cyclic-converted uracils and their use
EP3046932A4 (en) Evolved sortases and uses thereof
IL235216A0 (en) Aqueous and lyophilized formulations of antibody against cd40
HUE036038T2 (hu) Felület-oxidált alacsony fajlagos felületû grafit, eljárás annak elõállítására, és annak alkalmazása
AP2014007834A0 (en) Thermal contrast assay and reader
EP3083606A4 (en) Pyrimidines and use thereof
GB2514988B (en) Venting pump devices and methods for using the same
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
EP3046417A4 (en) METHOD OF USING ADIPOSE TISSUE DERIVED CELLS IN THE MODULATION OF PAIN AND / OR FIBROSIS
EP2976091C0 (de) Antioxidativ wirksame zusammensetzung und deren verwendung
GB201309178D0 (en) Enzyme and uses thereof
EP3036849A4 (en) Bs and ue, and methods used in the same
AU2013902966A0 (en) Improvements in shoes and the like
ZA201205434B (en) Coffins, sarcophagi, cinerary urns and the like

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees